Related Experiment Video
Updated: Jun 29, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Cellular and Mitochondrial Pathways Contribute to SGLT2 Inhibitors-mediated Tissue Protection: Experimental and
Raúl Lelio Sanz1, Sebastián García Menéndez1,2, Felipe Inserra3
1Departamento de Patologie et Pharmacologie, Instituto de Medicina y Biologia Experimental de Cuyo, Consejo Nacional de Investigación Cientifica y Tecnológica (IMBECU- CONICET), Mendoza 5500, Argentina.
Abstract:
In metabolic syndrome and diabetes, compromised mitochondrial function emerges as a critical driver of cardiovascular disease, fueling its development and persistence, culminating in cardiac remodeling and adverse events. In this context, angiotensin II - the main interlocutor of the renin-angiotensin-aldosterone system - promotes local and systemic oxidative inflammatory processes. To highlight, the low activity/expression of proteins called sirtuins negatively participates in these processes, allowing more significant oxidative imbalance, which impacts cellular and tissue responses, causing tissue damage, inflammation, and cardiac and vascular remodeling. The reduction in energy production of mitochondria has been widely described as a significant element in all types of metabolic disorders. Additionally, high sirtuin levels and AMPK signaling stimulate hypoxia- inducible factor 1 beta and promote ketonemia. Consequently, enhanced autophagy and mitophagy advance through cardiac cells, sweeping away debris and silencing the orchestra of oxidative stress and inflammation, ultimately protecting vulnerable tissue from damage. To highlight and of particular interest, SGLT2 inhibitors (SGLT2i) profoundly influence all these mechanisms. Randomized clinical trials have evidenced a compelling picture of SGLT2i emerging as game-changers, wielding their power to demonstrably improve cardiac function and slash the rates of cardiovascular and renal events. Furthermore, driven by recent evidence, SGLT2i emerge as cellular supermolecules, exerting their beneficial actions to increase mitochondrial efficiency, alleviate oxidative stress, and curb severe inflammation. Its actions strengthen tissues and create a resilient defense against disease. In conclusion, like a treasure chest brimming with untold riches, the influence of SGLT2i on mitochondrial function holds untold potential for cardiovascular health. Unlocking these secrets, like a map guiding adventurers to hidden riches, promises to pave the way for even more potent therapeutic strategies.
Insights
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular health by enhancing mitochondrial function and reducing oxidative stress and inflammation in metabolic disorders. These drugs offer a promising therapeutic strategy for protecting cardiac tissue and preventing adverse events.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Mitochondrial Biology
Background:
- Compromised mitochondrial function drives cardiovascular disease in metabolic syndrome and diabetes.
- Angiotensin II and low sirtuin activity exacerbate oxidative stress, inflammation, and cardiac remodeling.
- Reduced mitochondrial energy production is a hallmark of metabolic disorders.
Purpose of the Study:
- To investigate the role of SGLT2 inhibitors (SGLT2i) in modulating mitochondrial function and related pathways in cardiovascular disease.
- To elucidate the mechanisms by which SGLT2i exert cardioprotective effects in the context of metabolic disorders.
Main Methods:
- Review of randomized clinical trials and mechanistic studies on SGLT2 inhibitors.
- Analysis of SGLT2i effects on mitochondrial efficiency, oxidative stress, inflammation, and autophagy/mitophagy.
- Exploration of the interplay between sirtuins, AMPK, and hypoxia-inducible factors.
Main Results:
- SGLT2 inhibitors significantly improve cardiac function and reduce cardiovascular and renal events.
- SGLT2i enhance mitochondrial efficiency, decrease oxidative stress, and reduce inflammation.
- SGLT2i promote autophagy and mitophagy, clearing cellular debris and protecting cardiac tissue.
Conclusions:
- SGLT2 inhibitors demonstrate profound beneficial effects on mitochondrial function, offering a potent therapeutic strategy for cardiovascular protection in metabolic disorders.
- SGLT2i act as 'cellular supermolecules' by improving mitochondrial efficiency and reducing inflammation.
- Further research into SGLT2i's mitochondrial actions may unlock novel therapeutic avenues for cardiovascular health.
More Related Videos
Related Concept Videos
Secondary Active Transport
Glucose Absorption Into the Small Intestine
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Transcellular Transport of Solutes

